03 · What You Need to Know
Information Can Be Layered Without Being Hidden
Recruitment and informed consent answer different questions
An initial recruitment message usually asks something like: “Might this study be relevant enough that you want to learn more?”
The informed-consent process asks a much more consequential question: “Now that you understand what participation involves, do you choose to take part?”
Those questions do not require identical amounts of information.
FDA guidance for clinical investigations states that advertisements should generally be limited to information prospective participants need to determine their eligibility and interest. Depending on the study, appropriate recruitment information may include the investigator or research facility, purpose of the research, summary eligibility criteria, potential participation benefits when appropriate, time or other commitments, location, and contact information.
Recruitment therefore does not need to reproduce the full consent document. But researchers should not exploit that distinction to create an attractive first impression that is materially contradicted only after someone has invested time, traveled to a site, disclosed sensitive information, or otherwise become psychologically committed.
Informed consent requires substantially more than an advertisement
Under the U.S. Common Rule, unless an applicable waiver or alteration applies, informed consent must provide the information a reasonable person would want to have to make an informed decision and an opportunity to discuss that information.
Required elements include, as applicable, an explanation that the activity is research, its purposes, expected duration, procedures, reasonably foreseeable risks or discomforts, reasonably expected benefits, appropriate alternatives, confidentiality information, relevant information about research-related injury for research involving more than minimal risk, appropriate contacts, and the voluntary nature of participation.
Additional elements may be required depending on the research.
Other ethical frameworks express the principle somewhat differently, and jurisdiction-specific requirements vary. The broader expectation remains that consent is an information and communication process, not merely a signature collected after minimal disclosure.
The goal is not maximum information; it is decision-relevant understanding
More pages do not automatically produce better consent.
The revised Common Rule requires informed consent to begin, except in the case of broad consent, with a concise and focused presentation of the key information most likely to help someone understand why they might or might not want to participate. The consent information as a whole must be sufficiently detailed and organized to facilitate understanding rather than merely presenting isolated facts.
This is an important corrective to a common assumption: ethical disclosure is not an information dump.
Comprehensive disclosure
Provides the information necessary for an informed decision in sufficient detail and appropriate organization.
Exhaustive disclosure
Attempts to communicate every technical or procedural fact regardless of whether it helps the participant understand the decision.
The two are not the same. A consent document can be extremely long yet obscure the few facts most likely to affect someone's choice.
Think in layers rather than one enormous disclosure
For many studies, information can be organized progressively.
Initial invitation
Enough information to recognize that this is research, understand its basic purpose and participation opportunity, and decide whether to seek further information.
Eligibility or screening stage
Information necessary to understand what screening involves, including relevant privacy or consent requirements for information collected at that stage.
Informed-consent process
The key information and required details needed to make the actual participation decision, with an opportunity for questions and clarification.
During participation
New information that may affect willingness to continue should be communicated when required by the applicable framework and approved consent process.
Layering can make complex information easier to process. It should not be used to postpone unfavorable information until a participant feels too committed to withdraw.
Lead with what could realistically change the person's decision
The Common Rule's emphasis on “key information” provides a useful conceptual question even outside settings directly governed by that regulation: what would a prospective participant most need to understand to decide whether this study is right for them?
That answer depends on the study.
For one project, the central issue may be a six-month commitment. For another, it may be randomization, a placebo, sensitive interview questions, an invasive procedure, genetic analysis, foreseeable side effects, access to identifiable records, or the absence of direct clinical benefit.
A generic consent template can therefore satisfy a checklist while still communicating poorly if the facts most consequential to the actual decision are buried deep in the document.
“We don't want to bias them” is not a general permission to withhold information
This problem often appears in behavioral and social research.
A researcher may worry that revealing the exact hypothesis will change participants' behavior. If participants know the experiment examines conformity, stereotype activation, memory errors, or another psychological phenomenon, for example, that knowledge could affect the phenomenon being studied.
That scientific concern can be legitimate. It does not mean the researcher may independently decide to omit whatever information threatens the design.
Under the Common Rule, an IRB may approve a waiver or alteration of informed consent only when the applicable regulatory criteria are satisfied. These include specified findings concerning risk, rights and welfare, practicability, and, where appropriate, provision of additional pertinent information after participation. Different regulatory regimes may use different requirements.
Watch Out
Do not convert “revealing this might affect our results” into a do-it-yourself exemption from informed consent. When information that would ordinarily be disclosed must be withheld or altered for scientific reasons, determine whether formal ethics approval for that procedure is required.
Partial disclosure is different from lying
Not telling participants the complete hypothesis at the outset is not necessarily the same as giving them false information.
For example, describing a study at an appropriately general level may sometimes protect its scientific validity without making a false statement. In other research, however, investigators may propose active deception, such as giving participants a false explanation of a task or using a deceptive experimental manipulation.
These practices raise different ethical questions and may require specific review, consent alterations, and debriefing arrangements depending on the governing framework.
The researcher should not casually decide that deception is acceptable simply because the study is low risk or because deception is common in a discipline.
Some information cannot ethically be buried in technical detail
Researchers sometimes technically disclose a fact without communicating it effectively.
A statement that a study is randomized may appear on page eight while the opening pages repeatedly describe access to an intervention. A data-use provision may be embedded in dense institutional language. A lengthy list of risks may give minor inconveniences the same prominence as a risk that would matter far more to most participants.
Under the revised Common Rule, informed consent must be organized and presented to facilitate understanding of why someone might or might not want to participate. This pushes consent beyond formal inclusion toward meaningful communication.
Researchers should therefore distinguish “the information appears somewhere in the document” from “the information was communicated in a way that supports the decision.” The consent form is not an academic literature review. Nobody receives methodological virtue points for making the participant find the research question on page twelve.
Questions are part of the information process
No consent document can predict every concern an individual participant will have.
One person may care most about privacy. Another may need to know whether participation affects ordinary treatment. Someone else may want details about time commitment, recording, data sharing, compensation, withdrawal, or future use of samples.
OHRP describes informed consent as an active information-sharing process and emphasizes giving prospective participants ample opportunity to ask questions and seek clarification.
This means that adequate disclosure is not achieved simply by handing someone a document containing all required elements. Researchers also need a process through which relevant uncertainties can be addressed.
Information may need to continue after enrollment
Consent is not necessarily informationally complete forever at the moment of enrollment.
New findings can emerge. Risks may become better understood. Procedures may change through approved amendments. Information may arise that could reasonably affect willingness to continue.
OHRP notes that consent procedures may need to be revised when deficiencies or new information about foreseeable risks and potential benefits become available. Depending on the research and governing requirements, participants may need additional information or renewed consent.
This is another reason to understand consent as an ongoing process rather than a single disclosure event.
